[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366448-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366448-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","on-the-dilemma-of-using-single-ev-analysis-for-liquid-biopsy-the-challenge-of-low-abundance-of-tumor-evs-in-blood","On the dilemma of using single EV analysis for liquid biopsy - the challenge of low abundance of tumor EVs in blood","","Single extracellular vesicle (EV) analysis enables non-invasive cancer diagnostics by revealing tumor-specific biomarkers and supporting personalized treatment decisions. A major barrier for clinical translation is the low abundance of tumor-derived EVs (tEVs) in blood, which limits sensitivity, specificity, and detection accuracy. This review argues that analyzing a large number of single EVs can overcome sampling constraints. It also highlights improved tEV isolation, targeted enrichment, and high-throughput analysis to increase diagnostic performance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/on-the-dilemma-of-using-single-ev-analysis-for-liquid-biopsy-the-challenge-of-low-abundance-of-tumor-evs-in-blood/366448/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/on-the-dilemma-of-using-single-ev-analysis-for-liquid-biopsy-the-challenge-of-low-abundance-of-tumor-evs-in-blood/366448.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is single EV analysis promising for liquid biopsy in cancer diagnostics?","Question",{"text":63,"@type":64},"It can provide non-invasive insights into tumor-specific biomarkers and help enable personalized treatment strategies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the main technical dilemma addressed in the review?",{"text":68,"@type":64},"The low abundance of tumor-derived EVs (tEVs) in blood reduces the sensitivity, specificity, and accuracy of detection.",{"name":70,"@type":61,"acceptedAnswer":71},"How can the challenge of low tEV abundance be addressed?",{"text":72,"@type":64},"The review emphasizes analyzing a large number of single EVs and developing more efficient tEV isolation and targeted enrichment strategies, supported by high-throughput analysis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366448,1790477267,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Theranostics 2025, Vol. 15, Issue 16 8031  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2025; 15(16): 8031-8048. doi: 10.7150/thno.115131  \nReview  \nOn the dilemma of using single EV analysis for liquid biopsy: the challenge of low abundance of tumor EVs in blood  \nMeruyert Imanbekova, Mohul Sharma, and Sebastian Wachsmann-Hogiu􀀍 Department of Bioengineering, McGill University, Montreal, QC, H3A 0E9, Canada.  \n􀀍 Corresponding author: [sebastian.wachsmannhogiu@mcgill.ca](sebastian.wachsmannhogiu@mcgill.ca).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.04.05; Accepted: 2025.06.24; Published: 2025.07.24  \nAbstract  \nSingle extracellular vesicle (EV) analysis holds great promise for non-invasive cancer diagnostics, offering insights into tumor-specific biomarkers and enabling personalized treatment strategies. However, a significant challenge in the path towards clinical applications is the low abundance of tumor-derived EVs (tEVs) in biofluids, which reduces the sensitivity, specificity, and accuracy of detection. This review emphasizes the importance of analyzing a large number of single EVs to overcome this limitation. We estimate that less than 0.1% of total EVs could be from cancer cells in a mixed sample. Additionally, the development of more efficient tEVs isolation methods and targeted enrichment strategies, as well as high-throughput analysis techniques are crucial for improving diagnostic accuracy and advancing liquid biopsy applications in cancer care.  \nKeywords: extracellular vesicles, liquid biopsy, single EV analysis, low abundance of tumor EVs, non-invasive cancer diagnostics  \n1. Introduction  \nCancer remains one of the leading causes of morbidity and mortality worldwide, underscoring the critical need for early and accurate diagnostic methods. Current technologies for detecting cancer, particularly in its early stages, have made significant progress, but there are still challenges to overcome. Early-stage cancer detection is crucial for improving survival rates, as tumors are often more treatable when detected early. Imaging techniques are well-established for tumor detection, but their ability to detect early-stage cancers is limited by tumor size, location, and metabolic characteristics. They are often more useful for staging and monitoring rather than for initial detection in asymptomatic patients. Biomarker-based immunoassays show promise for early detection, particularly in high-risk individuals, but they are not universally applicable across all cancer types. Their current role is more about monitoring and screening rather than providing definitive early detection. Traditional biopsy techniques can be invasive and may not always  \nprovide a comprehensive view of tumor heterogeneity [1] .  \nLiquid biopsy, on the other hand, encompasses a range of minimally invasive techniques for analyzing tumor-derived materials in body fluids, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and cell-free RNA (cfRNA) (Figure 1) [2, 3] .  \nEach of these biomarkers offers distinct advantages and limitations: ctDNA enables mutation profiling but is often present in low concentrations, especially in early-stage disease [5]; CTCs provide rich phenotypic and genomic information, but are rare and difficult to isolate [7] . In contrast, EVs are abundantly released by most cell types, are stable in circulation, and carry a diverse cargo of proteins, lipids, and nucleic acids that reflect their cell of origin [8] . These properties make EVs an attractive and versatile source of biomarkers for disease diagnosis, prognosis, and monitoring, warranting further investigation in the context of liquid biopsy [9] .  \nFigure 1. Li","cbCaileuYgzDUNPM","https://ap.wps.com/l/cbCaileuYgzDUNPM","pdf",3078252,18,"English","# Introduction\n## Liquid biopsy and circulating biomarkers\n## EVs as a versatile biomarker source\n## Low abundance and analytical challenges\n## EV types and tumor-derived EVs","[{\"question\":\"Why is single EV analysis promising for liquid biopsy in cancer diagnostics?\",\"answer\":\"It can provide non-invasive insights into tumor-specific biomarkers and help enable personalized treatment strategies.\"},{\"question\":\"What is the main technical dilemma addressed in the review?\",\"answer\":\"The low abundance of tumor-derived EVs (tEVs) in blood reduces the sensitivity, specificity, and accuracy of detection.\"},{\"question\":\"How can the challenge of low tEV abundance be addressed?\",\"answer\":\"The review emphasizes analyzing a large number of single EVs and developing more efficient tEV isolation and targeted enrichment strategies, supported by high-throughput analysis.\"}]","On the dilemma of using single EV analysis for liquid biopsy - the challenge of low abundance of tumor EVs in blood | PDF",1790165628,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0aecb9bb35a222800c4574007e22e68d.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c58b942fe2326aacef96ffafab264608.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc4f4f6ad90799e36d34fdc52a024345.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2ec982a6b3dc69d3132b1f529f691bc.webp",980,1268]